Desmopressin - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:57:26Z

Switch SMW query from broadtable to table format for better layout with TOC

← Revisión anterior		Revisión del 21:57 20 mar 2026
Línea 135:		Línea 135:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Add SMW Indications by Condition query table

2026-03-20T18:54:40Z

Add SMW Indications by Condition query table

← Revisión anterior		Revisión del 18:54 20 mar 2026
Línea 125:		Línea 125:

	==Comments==		==Comments==

			==Indications by Condition==
			''The following table is automatically generated from disease/condition pages across WikEM.''

			{{#ask:[[Has DrugName::Desmopressin]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|mainlabel=-
			\|sort=Has Indication
			\|limit=50
			}}


	==See Also==		==See Also==

Kxl328: /* Adult Dosing */

2022-03-03T19:51:12Z

Adult Dosing

← Revisión anterior		Revisión del 19:51 3 mar 2022
Línea 27:		Línea 27:
	===Uremic Bleeding in Acute or Chronic Renal Failure===		===Uremic Bleeding in Acute or Chronic Renal Failure===
	*0.4 mcg/kg IV over 10 minutes		*0.4 mcg/kg IV over 10 minutes

			===DDAVP Clamp===
			*Eliminate unpredictable excretion of water from kidneys by stimulating V2-vasopressin receptors in the kidney, causing renal retention of water
			*2 mcg IV q8h<ref>Sood L et al. Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia. Am J Kidney Dis
			. 2013 Apr;61(4):571-8. doi: 10.1053/j.ajkd.2012.11.032. Epub 2012 Dec 23.</ref>

	==Pediatric Dosing==		==Pediatric Dosing==

Neil.m.young: Text replacement - "1 mg" to "1mg"

2016-07-20T07:31:51Z

Text replacement - "1 mg" to "1mg"

← Revisión anterior		Revisión del 07:31 20 jul 2016
Línea 3:		Línea 3:
	*Dosage Forms:		*Dosage Forms:
	**injectable solution: 4 mcg/mL		**injectable solution: 4 mcg/mL
	**tablet: 0.~~1 mg~~, 0.2mg		**tablet: 0.1mg, 0.2mg
	**nasal spray: 0.~~1 mg~~/ mL (5mL); Delivers 10 mcg/spray, 1.5mg/mL (2.5mL); Delivers 150 mcg/spray		**nasal spray: 0.1mg/ mL (5mL); Delivers 10 mcg/spray, 1.5mg/mL (2.5mL); Delivers 150 mcg/spray
	*Routes of Administration: IV, IM, SC, intranasal, oral		*Routes of Administration: IV, IM, SC, intranasal, oral
	*Common Trade Names: DDAVP, Stimate		*Common Trade Names: DDAVP, Stimate

Neil.m.young: Text replacement - "2 mg" to "2mg"

2016-07-20T03:45:59Z

Text replacement - "2 mg" to "2mg"

← Revisión anterior		Revisión del 03:45 20 jul 2016
Línea 3:		Línea 3:
	*Dosage Forms:		*Dosage Forms:
	**injectable solution: 4 mcg/mL		**injectable solution: 4 mcg/mL
	**tablet: 0.1 mg, 0.~~2 mg~~		**tablet: 0.1 mg, 0.2mg
	**nasal spray: 0.1 mg/ mL (5mL); Delivers 10 mcg/spray, 1.5mg/mL (2.5mL); Delivers 150 mcg/spray		**nasal spray: 0.1 mg/ mL (5mL); Delivers 10 mcg/spray, 1.5mg/mL (2.5mL); Delivers 150 mcg/spray
	*Routes of Administration: IV, IM, SC, intranasal, oral		*Routes of Administration: IV, IM, SC, intranasal, oral
Línea 13:		Línea 13:
	*PO:		*PO:
	**Initial: 0.05mg q 12 hr		**Initial: 0.05mg q 12 hr
	**Effective range: 0.1-1.~~2 mg~~ divided q 8-12 hr		**Effective range: 0.1-1.2mg divided q 8-12 hr
	*IV/SC: 2-4 mcg/day divided q12 hr or 1/10th the maintenance of intranasal dose		*IV/SC: 2-4 mcg/day divided q12 hr or 1/10th the maintenance of intranasal dose

Línea 23:		Línea 23:

	===Nocturnal Enuresis===		===Nocturnal Enuresis===
	*0.~~2 mgPO~~ qHS (up to 0.6mg/day)		*0.2mgPO qHS (up to 0.6mg/day)

	===Uremic Bleeding in Acute or Chronic Renal Failure===		===Uremic Bleeding in Acute or Chronic Renal Failure===
Línea 38:		Línea 38:
	====3 months to 12 years (oral)====		====3 months to 12 years (oral)====
	*Initial: 0.05mg q 12 hr		*Initial: 0.05mg q 12 hr
	*Effective range: 0.1-1.~~2 mg~~		*Effective range: 0.1-1.2mg

	====>12 years (oral)====		====>12 years (oral)====
	*Initial 0.05mg PO q 12 hr		*Initial 0.05mg PO q 12 hr
	*Effective range: 0.1-1.~~2 mg~~ divided q8-12 hr		*Effective range: 0.1-1.2mg divided q8-12 hr

	====3 months to 12 years (IV/SC)====		====3 months to 12 years (IV/SC)====
Línea 51:		Línea 51:

	===Nocturnal Enuresis===		===Nocturnal Enuresis===
	*>6 years: 0.~~2 mg~~ PO qHS; up to 0.6mg/day		*>6 years: 0.2mg PO qHS; up to 0.6mg/day

	===Hemophilia A & Von Willebrand Disease===		===Hemophilia A & Von Willebrand Disease===

Neil.m.young: Text replacement - "6 mg" to "6mg"

2016-07-19T09:45:41Z

Text replacement - "6 mg" to "6mg"

← Revisión anterior		Revisión del 09:45 19 jul 2016
Línea 51:		Línea 51:

	===Nocturnal Enuresis===		===Nocturnal Enuresis===
	*>6 years: 0.2 mg PO qHS; up to 0.~~6 mg~~/day		*>6 years: 0.2 mg PO qHS; up to 0.6mg/day

	===Hemophilia A & Von Willebrand Disease===		===Hemophilia A & Von Willebrand Disease===

Neil.m.young: Text replacement - "5 mg" to "5mg"

2016-07-18T20:44:23Z

Text replacement - "5 mg" to "5mg"

← Revisión anterior		Revisión del 20:44 18 jul 2016
Línea 4:		Línea 4:
	**injectable solution: 4 mcg/mL		**injectable solution: 4 mcg/mL
	**tablet: 0.1 mg, 0.2 mg		**tablet: 0.1 mg, 0.2 mg
	**nasal spray: 0.1 mg/ mL (5mL); Delivers 10 mcg/spray, 1.~~5 mg~~/mL (2.5mL); Delivers 150 mcg/spray		**nasal spray: 0.1 mg/ mL (5mL); Delivers 10 mcg/spray, 1.5mg/mL (2.5mL); Delivers 150 mcg/spray
	*Routes of Administration: IV, IM, SC, intranasal, oral		*Routes of Administration: IV, IM, SC, intranasal, oral
	*Common Trade Names: DDAVP, Stimate		*Common Trade Names: DDAVP, Stimate
Línea 12:		Línea 12:
	*Intranasal: 10-40 mcg/day qday or divided q8-12 hr		*Intranasal: 10-40 mcg/day qday or divided q8-12 hr
	*PO:		*PO:
	**Initial: 0.~~05 mg~~ q 12 hr		**Initial: 0.05mg q 12 hr
	**Effective range: 0.1-1.2 mg divided q 8-12 hr		**Effective range: 0.1-1.2 mg divided q 8-12 hr
	*IV/SC: 2-4 mcg/day divided q12 hr or 1/10th the maintenance of intranasal dose		*IV/SC: 2-4 mcg/day divided q12 hr or 1/10th the maintenance of intranasal dose
Línea 37:		Línea 37:

	====3 months to 12 years (oral)====		====3 months to 12 years (oral)====
	*Initial: 0.~~05 mg~~ q 12 hr		*Initial: 0.05mg q 12 hr
	*Effective range: 0.1-1.2 mg		*Effective range: 0.1-1.2 mg

	====>12 years (oral)====		====>12 years (oral)====
	*Initial 0.~~05 mg~~ PO q 12 hr		*Initial 0.05mg PO q 12 hr
	*Effective range: 0.1-1.2 mg divided q8-12 hr		*Effective range: 0.1-1.2 mg divided q8-12 hr

Neil.m.young: Text replacement - " ==" to "=="

2016-07-05T20:16:53Z

Text replacement - " ==" to "=="

← Revisión anterior		Revisión del 20:16 5 jul 2016
Línea 53:		Línea 53:
	*>6 years: 0.2 mg PO qHS; up to 0.6 mg/day		*>6 years: 0.2 mg PO qHS; up to 0.6 mg/day

	===Hemophilia A & Von Willebrand Disease ===		===Hemophilia A & Von Willebrand Disease===
	*0.3 mcg/kg IV over 15-30 minutes; for pre-op, give 30 minutes before procedure		*0.3 mcg/kg IV over 15-30 minutes; for pre-op, give 30 minutes before procedure
	*1 spray (150 mcg) per nostril (300 mcg total dose) if >12 years of age or >50 kg body weight		*1 spray (150 mcg) per nostril (300 mcg total dose) if >12 years of age or >50 kg body weight

Ostermayer: Text replacement - "Category:Drugs" to "Category:Pharmacology"

2016-03-22T15:54:19Z

Text replacement - "Category:Drugs" to "Category:Pharmacology"

← Revisión anterior		Revisión del 15:54 22 mar 2016
Línea 125:		Línea 125:
	==References==		==References==
	<references/>		<references/>
	[[Category:~~Drugs~~]]		[[Category:Pharmacology]]
	epocrates, medscape		epocrates, medscape

Janelim: references

2016-02-08T21:16:22Z

references

← Revisión anterior		Revisión del 21:16 8 feb 2016
Línea 126:		Línea 126:
	<references/>		<references/>
	[[Category:Drugs]]		[[Category:Drugs]]
			epocrates, medscape